A Phase 2 interventional study of Uprifosbuvir and Ruzasvir in Hepatitis C, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Hepatitis C by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Hepatitis C · Merck & Co., Inc.
Among the 92 studies in Hepatitis C by Merck & Co., Inc, this one is the 10th largest by enrollment of the 69 interventional ones that give a count, is one of 3 that started in 2016, is one of 20 in phase 2, and was the 88th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 92 studies in Hepatitis C by Merck & Co., Inc is open now. The open studies under Hepatitis C, anywhere →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 26 · Phase 3 13 · Phase 4 5
First in 1997; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 282 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 60 across the 69 interventional studies, 332 across the 23 observational. Of the 86 that completed or were terminated, 66 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 92 studies in Hepatitis C by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a nonrandomized, multi-site, open-label trial to evaluate a novel two-drug combination regimen (uprifosbuvir [MK-3682] 450 mg + ruzasvir [RZR; MK-8408] 180 mg once daily [q.d.] for 12 weeks) in male and female treatment-naïve (TN) or treatment-experienced (TE) participants with chronic hepatitis C virus (HCV) infection genotype (GT) GT1, GT2, GT3, GT4, GT5, or GT6 who have not previously received HCV direct-acting antiviral (DAA) therapy. Cirrhotic (C) and non-cirrhotic (NC) participants with and without human immunodeficiency virus (HIV) co-infection will be enrolled.
Any GT that meets virologic futility criteria will be given the option of extending treatment with uprifosbuvir + RZR to 16 weeks with ribavirin (RBV) added.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Male and female participants with HCV GT1a or GT1b infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Ribavirin
Male and female participants with HCV GT2 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Ribavirin
Male and female participants with HCV GT3 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Ribavirin
Male and female participants with HCV GT4 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Ribavirin
Male and female participants with HCV GT5 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Ribavirin
Male and female participants with HCV GT6 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Ribavirin
Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.
Also known as: MK-3682
Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
Also known as: MK-8408
RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Completing Study Therapy (SVR12)
Plasma levels of hepatitis C virus (HCV) ribonucleic acid (RNA) were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 on blood samples drawn from participants. SVR12 is the absence of detectable RNA of the hepatitis C virus, (\<lower limit of quantification \[LLOQ\] of 15 IU/mL) for at least 12 weeks after completing treatment.
Time frame: 12 weeks after completing study therapy (Week 24)
Percentage of Participants Experiencing an Adverse Event (AE)
An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example ), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
Time frame: Up to Week 14
Percentage of Participants Experiencing an AE of Clinical Importance (ECI)
Adverse events of clinical importance, excluding overdoses include, but is not limited to, significant changes in alanine aminotransferase, aspartate aminotransferase, blood creatinine, glomerular filtration rate or hepatitis B reactivation.
Time frame: Up to Week 14
Percentage of Participants Experiencing a Serious Adverse Event (SAE)
A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is an other important medical event; is a cancer; is associated with an overdose.
Time frame: Up to Week 14
Percentage of Participants Experiencing a Drug-related AE
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example ), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE is determined by the investigator to be related to the use of the drug.
Time frame: Up to Week 14
Percentage of Participants Experiencing a Drug-related SAE
A SAE is any AE occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is an other important medical event; is a cancer; is associated with an overdose. A drug-related SAE is determined by the investigator to be related to the use of the drug.
Time frame: Up to Week 14
Percentage of Participants Discontinuing Study Therapy Due to an AE
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example ), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
Time frame: Up to Week 12
Percentage of Participants With SVR 24 Weeks After Completing Study Therapy (SVR24)
Plasma levels of HCV RNA) were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 on blood samples drawn from participants. SVR24 is the absence of detectable RNA of the hepatitis C virus (\<LLOQ of 15 IU/mL), for at least 24 weeks after completing treatment.
Time frame: 24 weeks after completing study therapy (Week 36)
Percentage of Participants With Virologic Failure
Virologic failure is the detection of HCV RNA among participants who do not discontinue study for non-treatment-related reasons, either due to on-treatment failure defined as either non-response where HCV RNA is detected at end of treatment without HCV RNA \<LLOQ having been achieved while on treatment; rebound defined as \>1 log10 IU/mL increase in HCV RNA from nadir while on treatment and confirmed from a separate blood draw within 2 weeks; or virologic breakthrough which is confirmed HCV RNA ≥LLOQ (target detected, quantifiable \[TD(q)\]) after being \<LLOQ previously while on treatment. Confirmation is defined as an HCV RNA ≥LLOQ from a separate blood draw repeated within 2 weeks; or relapse post-treatment. where there is a confirmed HCV RNA ≥LLOQ \[TD(q)\] following end of all study therapy, after becoming undetectable (target not detected \[TND\]) at end of treatment. Confirmation is defined as an HCV RNA ≥LLOQ from a separate blood draw repeated within 2 weeks.
Time frame: Up to Week 24
Males and females of at least 18 years of age, with chronic Hepatitis C Virus (HCV) infection were enrolled in this study.
| Milestone | HCV Genotype (GT) 1 | HCV GT2 | HCV GT3 | HCV GT4 | HCV GT5 | HCV GT6 |
|---|---|---|---|---|---|---|
| Started | 78 | 47 | 61 | 56 | 18 | 22 |
| Completed | 73 | 41 | 57 | 55 | 18 | 21 |
| Not completed | 5 | 6 | 4 | 1 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 5 | 3 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 1 | 0 | 0 | 0 | 0 |
Plasma levels of hepatitis C virus (HCV) ribonucleic acid (RNA) were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 on blood samples drawn from participants. SVR12 is the absence of detectable RNA of the hepatitis C virus, (\<lower limit of quantification \[LLOQ\] of 15 IU/mL) for at least 12 weeks after completing treatment.
| Percentage of participants | HCV GT1 | HCV GT2 | HCV GT3 | HCV GT4 | HCV GT5 | HCV GT6 |
|---|---|---|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Completing Study Therapy (SVR12) | 92.3 (84.0 to 97.1) | 91.5 (79.6 to 97.6) | 73.8 (60.9 to 84.2) | 98.2 (90.4 to 100.0) | 100.0 (81.5 to 100.0) | 90.9 (70.8 to 98.9) |
An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example ), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
| Percentage of participants | HCV GT1 | HCV GT2 | HCV GT3 | HCV GT4 | HCV GT5 | HCV GT6 |
|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing an Adverse Event (AE) | 60.3 | 61.7 | 57.4 | 55.4 | 77.8 | 77.3 |
Adverse events of clinical importance, excluding overdoses include, but is not limited to, significant changes in alanine aminotransferase, aspartate aminotransferase, blood creatinine, glomerular filtration rate or hepatitis B reactivation.
| Percentage of participants | HCV GT1 | HCV GT2 | HCV GT3 | HCV GT4 | HCV GT5 | HCV GT6 |
|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing an AE of Clinical Importance (ECI) | 1.3 | 2.1 | 1.6 | 3.6 | 0 | 0 |
A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is an other important medical event; is a cancer; is associated with an overdose.
| Percentage of participants | HCV GT1 | HCV GT2 | HCV GT3 | HCV GT4 | HCV GT5 | HCV GT6 |
|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing a Serious Adverse Event (SAE) | 3.8 | 2.1 | 1.6 | 3.6 | 0 | 0 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example ), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE is determined by the investigator to be related to the use of the drug.
| Percentage of participants | HCV GT1 | HCV GT2 | HCV GT3 | HCV GT4 | HCV GT5 | HCV GT6 |
|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing a Drug-related AE | 37.2 | 27.7 | 36.1 | 28.6 | 50.0 | 22.7 |
A SAE is any AE occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is an other important medical event; is a cancer; is associated with an overdose. A drug-related SAE is determined by the investigator to be related to the use of the drug.
| Percentage of participants | HCV GT1 | HCV GT2 | HCV GT3 | HCV GT4 | HCV GT5 | HCV GT6 |
|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing a Drug-related SAE | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example ), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
| Percentage of participants | HCV GT1 | HCV GT2 | HCV GT3 | HCV GT4 | HCV GT5 | HCV GT6 |
|---|---|---|---|---|---|---|
| Percentage of Participants Discontinuing Study Therapy Due to an AE | 1.3 | 2.1 | 1.6 | 1.8 | 0 | 4.5 |
Plasma levels of HCV RNA) were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 on blood samples drawn from participants. SVR24 is the absence of detectable RNA of the hepatitis C virus (\<LLOQ of 15 IU/mL), for at least 24 weeks after completing treatment.
| Percentage of participants | HCV GT1 | HCV GT2 | HCV GT3 | HCV GT4 | HCV GT5 | HCV GT6 |
|---|---|---|---|---|---|---|
| Percentage of Participants With SVR 24 Weeks After Completing Study Therapy (SVR24) | 89.7 (80.8 to 95.5) | 85.1 (71.7 to 93.8) | 72.1 (59.2 to 82.9) | 96.4 (87.7 to 99.6) | 100.0 (81.5 to 100.0) | 81.8 (59.7 to 94.8) |
Virologic failure is the detection of HCV RNA among participants who do not discontinue study for non-treatment-related reasons, either due to on-treatment failure defined as either non-response where HCV RNA is detected at end of treatment without HCV RNA \<LLOQ having been achieved while on treatment; rebound defined as \>1 log10 IU/mL increase in HCV RNA from nadir while on treatment and confirmed from a separate blood draw within 2 weeks; or virologic breakthrough which is confirmed HCV RNA ≥LLOQ (target detected, quantifiable \[TD(q)\]) after being \<LLOQ previously while on treatment. Confirmation is defined as an HCV RNA ≥LLOQ from a separate blood draw repeated within 2 weeks; or relapse post-treatment. where there is a confirmed HCV RNA ≥LLOQ \[TD(q)\] following end of all study therapy, after becoming undetectable (target not detected \[TND\]) at end of treatment. Confirmation is defined as an HCV RNA ≥LLOQ from a separate blood draw repeated within 2 weeks.
| Percentage of participants | HCV GT1 | HCV GT2 | HCV GT3 | HCV GT4 | HCV GT5 | HCV GT6 |
|---|---|---|---|---|---|---|
| Percentage of Participants With Virologic Failure | 3.8 | 2.1 | 23.0 | 0 | 0 | 13.6 |
Collected over Up to Week 14. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HCV GT1 | 0/78 (0%) | 3/78 (3.8%) | 28/78 (35.9%) |
| HCV GT2 | 0/47 (0%) | 1/47 (2.1%) | 20/47 (42.6%) |
| HCV GT3 | 0/61 (0%) | 1/61 (1.6%) | 30/61 (49.2%) |
| HCV GT4 | 0/56 (0%) | 2/56 (3.6%) | 22/56 (39.3%) |
| HCV GT5 | 0/18 (0%) | 0/18 (0%) | 14/18 (77.8%) |
| HCV GT6 | 0/22 (0%) | 0/22 (0%) | 10/22 (45.5%) |
| Event | HCV GT1 | HCV GT2 | HCV GT3 | HCV GT4 | HCV GT5 | HCV GT6 |
|---|---|---|---|---|---|---|
| Ovarian cystReproductive system and breast disorders | 0/78 | 1/47 | 0/61 | 0/56 | 0/18 | 0/22 |
| DiarrhoeaGastrointestinal disorders | 0/78 | 0/47 | 0/61 | 1/56 | 0/18 | 0/22 |
| Abscess limbInfections and infestations | 0/78 | 0/47 | 0/61 | 1/56 | 0/18 | 0/22 |
| FallInjury, poisoning and procedural complications | 0/78 | 0/47 | 1/61 | 0/56 | 0/18 | 0/22 |
| Ammonia increasedInvestigations | 0/78 | 0/47 | 1/61 | 0/56 | 0/18 | 0/22 |
| Blood creatinine increasedInvestigations | 0/78 | 0/47 | 1/61 | 0/56 | 0/18 | 0/22 |
| Glomerular filtration rate decreasedInvestigations | 0/78 | 0/47 | 1/61 | 0/56 | 0/18 | 0/22 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/78 | 0/47 | 1/61 | 0/56 | 0/18 | 0/22 |
| Acute kidney injuryRenal and urinary disorders | 0/78 | 0/47 | 1/61 | 0/56 | 0/18 | 0/22 |
| Acute coronary syndromeCardiac disorders | 1/78 | 0/47 | 0/61 | 0/56 | 0/18 | 0/22 |
| Event | HCV GT1 | HCV GT2 | HCV GT3 | HCV GT4 | HCV GT5 | HCV GT6 |
|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 14/78 | 5/47 | 5/61 | 4/56 | 0/18 | 1/22 |
| Upper respiratory tract infectionInfections and infestations | 2/78 | 3/47 | 2/61 | 2/56 | 3/18 | 1/22 |
| Blood creatine phosphokinase increasedInvestigations | 0/78 | 0/47 | 0/61 | 1/56 | 3/18 | 0/22 |
| HeadacheNervous system disorders | 7/78 | 5/47 | 10/61 | 8/56 | 2/18 | 1/22 |
| Abdominal painGastrointestinal disorders | 1/78 | 1/47 | 1/61 | 2/56 | 2/18 | 1/22 |
| DiarrhoeaGastrointestinal disorders | 3/78 | 2/47 | 2/61 | 3/56 | 2/18 | 1/22 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/78 | 0/47 | 1/61 | 2/56 | 2/18 | 0/22 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/78 | 0/47 | 1/61 | 0/56 | 2/18 | 0/22 |
| AstheniaGeneral disorders | 5/78 | 1/47 | 6/61 | 0/56 | 0/18 | 0/22 |
| ConstipationGastrointestinal disorders | 2/78 | 1/47 | 1/61 | 1/56 | 0/18 | 2/22 |
| Age, Continuous(Years) | HCV GT1 | HCV GT2 | HCV GT3 | HCV GT4 | HCV GT5 | HCV GT6 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 47.9 ± 12.6 | 52.7 ± 11.9 | 48.4 ± 10.1 | 46.4 ± 13.0 | 57.4 ± 12.4 | 53.3 ± 11.0 | 49.5 ± 12.2 |
| Sex: Female, Male(Participants) | HCV GT1 | HCV GT2 | HCV GT3 | HCV GT4 | HCV GT5 | HCV GT6 | Total |
|---|---|---|---|---|---|---|---|
| Female | 35 | 24 | 27 | 23 | 11 | 6 | 126 |
| Male | 43 | 23 | 34 | 33 | 7 | 16 | 156 |
| Race (NIH/OMB)(Participants) | HCV GT1 | HCV GT2 | HCV GT3 | HCV GT4 | HCV GT5 | HCV GT6 | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 2 | 2 | 0 | 1 | 22 | 29 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 0 | 1 | 0 | 0 | 4 |
| Black or African American | 4 | 0 | 1 | 8 | 9 | 0 | 22 |
| White | 69 | 44 | 57 | 47 | 4 | 0 | 221 |
| More than one race | 1 | 0 | 1 | 0 | 4 | 0 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Nov 2016 to primary completion in Dec 2017, 13 months.
Results were first posted in Dec 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Uprifosbuvir · Ruzasvir